Flockerzi Fidelis Andrea, Hohneck Johannes, Saar Matthias, Bohle Rainer Maria, Stahl Phillip Rolf
Department of Pathology, Saarland University Medical Center, 66424 Homburg, Germany.
Department of Urology and Pediatric Urology, University Hospital, 52074 Aachen, Germany.
Diagnostics (Basel). 2023 Jun 29;13(13):2211. doi: 10.3390/diagnostics13132211.
Prostate cancer is one of the most common malignancies worldwide, showing a wide range of clinical behaviors. Therefore, several treatment options arise out of the diagnosis "prostate cancer". For this reason, it is desirable to find novel prognostic and predictive markers. In former studies, we showed that THSD7A expression is associated with unfavorable prognostic parameters in prostate cancer and is linked to a high expression of focal adhesion kinase (FAK). Recently, scavenger receptor class A member 5 (SCARA5) was reported to be the downstream gene of THSD7A in esophageal squamous cell carcinoma. SCARA5 is believed to play an important role in the development and progression of several different tumor types. Most studies describe SCARA5 as a tumor suppressor. There is also evidence that SCARA 5 interacts with FAK. To examine the role of SCARA5 as a potential biomarker in prostate cancer, a total of 461 prostate cancers were analyzed via immunohistochemistry using tissue microarrays. Furthermore, we compared the expression level of SCARA5 with our previously collected data on THSD7A and FAK. High SCARA5 expression was associated with advanced tumor stage ( < 0.001), positive nodal status ( < 0.001) and high Gleason-score ( < 0.001). At least, strongly SCARA5-positive cancers were associated with THSD7A-positivity. There was no significant association between SCARA5 expression level and FAK expression level. To our knowledge, we are the first to investigate the role of SCARA5 in prostate cancer and we demonstrated that SCARA5 might be a potential biomarker in prostate cancer.
前列腺癌是全球最常见的恶性肿瘤之一，临床表现多样。因此，针对“前列腺癌”的诊断出现了多种治疗选择。出于这个原因，寻找新的预后和预测标志物是很有必要的。在之前的研究中，我们发现THSD7A表达与前列腺癌不良预后参数相关，且与粘着斑激酶（FAK）的高表达有关。最近，据报道，清道夫受体A类成员5（SCARA5）是食管鳞状细胞癌中THSD7A的下游基因。SCARA5被认为在几种不同肿瘤类型的发生和发展中起重要作用。大多数研究将SCARA5描述为一种肿瘤抑制因子。也有证据表明SCARA5与FAK相互作用。为了研究SCARA5作为前列腺癌潜在生物标志物的作用，我们使用组织芯片通过免疫组织化学分析了总共461例前列腺癌。此外，我们将SCARA5的表达水平与我们之前收集的关于THSD7A和FAK的数据进行了比较。SCARA5高表达与肿瘤晚期（<0.001）、阳性淋巴结状态（<0.001）和高Gleason评分（<0.001）相关。至少，SCARA5强阳性的癌症与THSD7A阳性相关。SCARA5表达水平与FAK表达水平之间无显著相关性。据我们所知，我们是首个研究SCARA5在前列腺癌中作用的，并且我们证明了SCARA5可能是前列腺癌的一种潜在生物标志物。
